LIDDS engages in researching and developing medicines and drugs for the treatment of prostate cancer... Read more
LIDDS engages in researching and developing medicines and drugs for the treatment of prostate cancer... Read more
News
Nov 21, 2024
Marketscreener
Liddspharma: LIDDS AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
Feb 22, 2024
Marketscreener
Liddspharma: LIDDS AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Mar 23, 2023
Global Legal Chronicle
Liddspharma: LIDDS AB's SEK 48.6 Million Rights Issue
Mar 13, 2022
Life Care News
Liddspharma: Report from Extraordinary General Meeting in LIDDS
Mar 04, 2022
FinanzNachrichten
Liddspharma: LIDDS AB: LIDDS publishes agenda for the company's Capital Markets Day 2022
Feb 24, 2022
FinanzNachrichten
Liddspharma: LIDDS AB: Statement from LIDDS regarding convertible note agreement
Feb 23, 2022
FirstWord Pharma
Liddspharma: LIDDS AB (publ) Year-end report 2021
Feb 23, 2022
FinanzNachrichten
Liddspharma: LIDDS AB: LIDDS secures financing of up to 40.8 MSEK to create foundation for new partnerships based on the NanoZolid technology
Feb 22, 2022
FE Investegate
Liddspharma: LIDDS AB : Notice of Extraordinary General Meeting in LIDDS AB (publ)
Feb 21, 2022
StreetInsider
Press Release: Liddspharma : LIDDS Next Step with NanoZolid formulated docetaxel